To examine the potential of anti‐LVRN mAb for clinical application, we conjugated monomethylauristatin E (MMAE, a potent anti‐cancer microtubule‐targeting agent) to control mAb (POG2, mouse anti‐porcine integrin α6, raised in our laboratory)[9] and anti‐LVRN mAb (5‐23) via a valine‐citrulline linker. Here, LVRN is linked to cancer.